Stockscreener 앱 받기
9.905
72.91%
-26.66
시간 외 거래:
10.05
0.145
+1.46%
Maplight Therapeutics Inc 주식(MPLT)의 최신 뉴스
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results - Investing.com Canada
Wolfe cuts MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia (MPLT) - Seeking Alpha
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - MarketBeat
MapLight dives despite positive data for schizophrenia drug - BioPharma Dive
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
Maplight Therapeutics (NASDAQ:MPLT) Sets New 12-Month LowTime to Sell? - MarketBeat
MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data - Investing.com Canada
Raymond James cuts MapLight Therapeutics stock price target on efficacy data - Investing.com Canada
Jefferies reiterates MapLight Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics (MPLT) Faces Stock Decline Despite Positiv - GuruFocus
BMO reiterates Outperform on MapLight stock after trial data By Investing.com - Investing.com Canada
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
MPLT: ML-007C-MA met key efficacy and safety endpoints in Phase 2 schizophrenia trial, supporting Phase 3 plans - TradingView
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia - marketscreener.com
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
MapLight schizophrenia drug meets phase 2 trial primary endpoint - Investing.com
MapLight Therapeutics stock tumbles 40% on trial results - Investing.com
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila Times
MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia - Stock Titan
MapLight Therapeutics Inc (MPLT) Cash Flow - TradingKey
MPLT|MapLight Therapeutics Inc|Price:36.560|Chg%:+1.330 - TradingKey
TradingKey - TradingKey
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? - Yahoo! Finance Canada
MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT - TradingView
MAPLIGHT THERAPEUTICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $35 - webull.com
Canaccord raises MapLight Therapeutics price target on trial data By Investing.com - Investing.com Canada
Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock - simplywall.st
Wall Street Analysts Are Bullish on Top NA Picks - The Globe and Mail
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
Form 4 MapLight Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
MapLight Therapeutics CSO James Woodruff sells $673k in shares for tax - Investing.com UK
MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says - marketscreener.com
BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46 - Moomoo
UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating - Moomoo
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock By Investing.com - Investing.com Australia
MPLT Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
UBS raises MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics general counsel sells $607,870 in shares By Investing.com - Investing.com South Africa
MapLight Therapeutics general counsel sells $607,870 in shares - Investing.com
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock - Investing.com
BMO Capital Initiates MapLight Therapeutics at Outperform With $46 Price Target - marketscreener.com
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
MapLight Therapeutics (MPLT) Coverage Initiated with Outperform Rating and Price Target - GuruFocus
Form 4 MapLight Therapeutics Inc For: 20 July By Investing.com - Investing.com Nigeria
Maplight Therapeutics Insider Sold Shares Worth $1,372,668, According to a Recent SEC Filing - marketscreener.com
MapLight Therapeutics (MPLT) CDO sells 36K shares via tax and plan trades - Stock Titan
MapLight Therapeutics (MPLT) CAO and interim CFO reports 36,979-share stock sale - Stock Titan
MapLight Therapeutics Insider Sold Shares Worth $5,443,722, According to a Recent SEC Filing - marketscreener.com
Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common shares - Bitget
Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common shares - Bitget
Form 144 MapLight Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Form 4 MapLight Therapeutics Inc For: 17 July By Investing.com - Investing.com South Africa
1.97%
0.83%
자본화:
|
볼륨(24시간):